Jason Gehrke

immunology and genetic disease @ third rock ventures

[Jason Gehrke @Jason__Gehrke]

Very pleased to announce BEAM-201, a multiplex base edited allo CAR-T therapy for T-ALL. 4x simultaneous base edits (96-99% editing at all four targets), 85% CAR+, and robust, dose dependent tumor control in vitro/in vivo. Fantastic achievement by the whole team @BeamTx.

[Patrick Hsu @pdhsu]

an absolute shame. @harvard cutting PhD admissions

"The Organismic and Evolutionary Biology department will shrink its class size by roughly 75 percent to three new Ph.D. students [...] Molecular and Cellular Biology will reduce its figure to four new students, and Chemistry and Chemical Biology will go down to four or five admits"

https://t.co/Q21WLdMpBT

[Jason Gehrke @Jason__Gehrke]

@AppleHelix Costs might be relatively similar (and negligible relative to overall development costs) but it’s much faster/higher POS to create an antibody DC these days. Small molecule medchem can be long/unpredictable, but typically you can get an antibody to DC in 12-18 months

[Jason Gehrke @Jason__Gehrke]

@Prof_Oak_ Slide 11 indicates they used standard and enhanced LD protocols - did you catch which patients got which LD? Interesting PK profile for an HLA-intact product

[Max Mamonkin @MaxMamonkin]

Incredible results with GD2 CART in neuroblastoma. Huge congratulations to the Bambino Gesu team https://t.co/vkKZr3e67H

[Jason Gehrke @Jason__Gehrke]

@zhaoweiasu @labratorytenant CD5 expression on healthy T cells decreases rapidly in response to CAR binding. We don’t see the CD5 CAR substantially protect against allorejection in our models.

[Jason Gehrke @Jason__Gehrke]

@Real_Poobah @AndrewE_Dunn Translating the platform from HEK cells to clinical application will require 100s of millions in focused investment and a large dedicated team. It’s better for the science to go somewhere where it’s the sole focus IMO.

[Latest News from Business Wire @NewsFromBW]

Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines https://t.co/VdtcF7mM0R

[Jason Gehrke @Jason__Gehrke]

@andyscharenberg Where is the bar for commercial viability and significant patient uptake? more stringent LD = better responses for current gen allo, but also more infections and less accessibility. Not sure either of the above approaches enables broad treatment.

[Jason Gehrke @Jason__Gehrke]

@MaxMamonkin Thanks Max, appreciate all your help and advice along the way. Now onto the clinic.

[David R. Liu @davidrliu]

Congratulations to @JKeithJoung for winning the 2022 Ho-Am Prize in Medicine for his many contributions to advancing the field of genome editing! 👏🍻🎉
https://t.co/RrEK0wcY7I

[Jason Gehrke @Jason__Gehrke]

@JKeithJoung @JulesGrunewald @ReganSzalay @elizajaneholtz We’ll miss you Jules! Can’t wait to stop by the Grunewald Lab next time I’m in Munich

[David R. Liu @davidrliu]

Today we report in @CellCellPress an engineered virus-like particle (eVLP) platform that mediates efficient in vivo delivery of therapeutic proteins, including base editors and Cas9 nuclease, resulting in therapeutic editing in multiple mouse organs. 1/14
https://t.co/v1yBl296L6

[Alex Sigal @sigallab]

We have completed our first experiments on neutralization of Omicron by Pfizer BNT162b2 vaccination elicited immunity

Manuscript available at
https://t.co/rGaEB9GdmS

and should be available on medRxiv in the coming days

[John Evans @john_evans3]

New base editing cell therapy data at SITC!

Focusing here on CD5 CART (relevant for T cell lymphomas), we make 5 different edits simultaneously at 94%+ efficiency, without double strand breaks:
https://t.co/RyOeGygeNk

[John Evans @john_evans3]

Excited to report our latest progress in our 3Q filing!

Most importantly, the BEAM-101 IND is now open, designated safe to proceed by the FDA.

BEAM-102 IND-enabling studies are also underway.

https://t.co/MQqYVfGKGA

[N @nosignul]

$SANA Biotech announced that the company entered into an agreement with Beam Therapeutics Inc. $BEAM for non-exclusive commercial rights to Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs. https://t.co/976cdIBYGC

[Wei Zhao @zhaoweiasu]

It’s a good time to remind everyone of the data from $BEAM: multiplex base editing does not alter T cell karyotype or growth (but multiplex Cas9 editing does)

[David R. Liu @davidrliu]

A thread: Many talented scientists including Alexis Komor and @NicoleGaudelli worked tirelessly starting in 2013 to develop and apply cytosine and adenine base editors, systems that directly edit targeted DNA base pairs in living cells without cutting the DNA double helix./1

[Jason Gehrke @Jason__Gehrke]

https://t.co/RQJjWaRcKh

[Jason Gehrke @Jason__Gehrke]

Interested in using base editors and nucleases to engineer the next generation of T and NK cell therapies? Join us! My group is hiring at the Assoc Dir, Sr Sci, and Sci levels. DM here or apply via link below 👇